U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Surmasis Pharmaceutical - 553686 - 06/22/2020
  1. Warning Letters

CLOSEOUT LETTER

Surmasis Pharmaceutical MARCS-CMS 553686 —

Delivery Method:
UPS Next Day
Product:
Drugs
Recipient:
Recipient Name
Mr. Lorne C. Scharnberg
Recipient Title
CEO
Surmasis Pharmaceutical

4020 Gannett Avenue
Des Moines, IA 50321
United States

Issuing Office:
Division of Pharmaceutical Quality Operations III

United States

(313) 393-8100

Dear Mr. Scharnberg:

The Food and Drug Administration has completed evaluation of your corrective actions in response to our Warning Letter #553686 dated November 6, 2018. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Nicholas F. Lyons
Director of Compliance
Division of Pharmaceutical Quality Operations III

Back to Top